Ju, Hee Young’s team published research in Cancer Research and Treatment in 2022 | 112-63-0

Cancer Research and Treatment published new progress about Adolescent, mammalian. 112-63-0 belongs to class esters-buliding-blocks, and the molecular formula is C19H34O2, COA of Formula: C19H34O2.

Ju, Hee Young; Park, Meerim; Lee, Jun Ah; Park, Hyeon Jin; Park, Seog Yun; Kim, June Hyuk; Kang, Hyun Guy; Yang, Hee Chul; Park, Byung-Kiu published the artcile< Vincristine, irinotecan, and temozolomide as a salvage regimen for relapsed or refractory sarcoma in children and young adults>, COA of Formula: C19H34O2, the main research area is vincristine irinotecan temozolomide salvage therapy antitumor agent sarcoma; Irinotecan; Salvage therapy; Sarcoma; Temozolomide; Vincristine.

No standard salvage regimen is available for relapsed or refractory sarcoma. We investigated the efficacy and toxicity of the vincristine, irinotecan, and temozolomide combination (VIT) for relapsed or refractory sarcomas of variable histol. in children and young adults. We retrospectively reviewed data from the relapsed or refractory sarcoma patients who were treated with VIT. The VIT protocol was given every 3 wk as follows: vincristine, 1.5 mg/m2 i.v. on day 1, irinotecan, 50 mg/m2 /day i.v. on days 1-5, and temozolomide, 100 mg/m2 /day orally on days 1-5. A total of 26 patients (12 males) with various sarcoma histol. were included in the study. Most common diagnosis was rhabdomyosarcoma (n=8) followed by osteosarcoma (n=7). Median age at the start of VIT was 18.5 years (range, 2.0 to 39.9). VIT was delivered as 2nd to 7th line of treatment, with 4th line most common (9/26, 34.6%). Median number of VIT courses given was 3 (range, 1 to 18). Of the 25 evaluable patients, there was two partial response (PR) and 11 stable disease (SD) with an overall control rate (complete remission+PR+SD) of 52%. PR was seen in one (50%) of the two evaluable patients with Ewing sarcoma and one (14.3%) of the seven patients with osteosarcoma. Overall survival and progression-free survival rates were 79.3% and 33.9% at 1 yr, and 45.5% and 25.4% at 2 years, resp. There was no treatment-related mortality. Conclusion The VIT regimen was effective and relatively safe in our cohort of sarcoma patients.

Cancer Research and Treatment published new progress about Adolescent, mammalian. 112-63-0 belongs to class esters-buliding-blocks, and the molecular formula is C19H34O2, COA of Formula: C19H34O2.

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics